Teyi Pharmaceutical Group Co.,Ltd (SHE:002728)
11.83
+0.19 (1.63%)
Feb 3, 2026, 3:04 PM CST
SHE:002728 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 923.16 | 686.91 | 1,066 | 886.15 | 757.93 | 632.22 |
Other Revenue | 0.88 | 0.88 | 0.74 | 0.43 | 0.23 | 0.48 |
| 924.04 | 687.79 | 1,067 | 886.57 | 758.16 | 632.7 | |
Revenue Growth (YoY) | 18.84% | -35.55% | 20.38% | 16.94% | 19.83% | -31.31% |
Cost of Revenue | 405.72 | 386.47 | 467.98 | 451.83 | 356.12 | 330.93 |
Gross Profit | 518.32 | 301.32 | 599.23 | 434.74 | 402.04 | 301.76 |
Selling, General & Admin | 368.48 | 225.54 | 240.67 | 176.38 | 175.95 | 153.87 |
Research & Development | 39.72 | 43.33 | 43.06 | 38.01 | 37.78 | 36.5 |
Other Operating Expenses | 5.55 | 2.05 | 9.38 | 1.75 | 9.27 | 8.19 |
Operating Expenses | 413.4 | 270.89 | 293.19 | 216.74 | 224.72 | 197.63 |
Operating Income | 104.92 | 30.43 | 306.04 | 217.99 | 177.33 | 104.13 |
Interest Expense | -4.97 | -5.32 | -16.36 | -29.13 | -29.51 | -42.72 |
Interest & Investment Income | 5.62 | 10.34 | 12.34 | 8.55 | 12.14 | 16.96 |
Other Non Operating Income (Expenses) | 0.47 | -0.45 | -0.4 | -1.44 | -0.42 | -0.6 |
EBT Excluding Unusual Items | 106.04 | 34.99 | 301.61 | 195.97 | 159.53 | 77.77 |
Impairment of Goodwill | -11.63 | -11.63 | -13.17 | - | -23.06 | -22.42 |
Gain (Loss) on Sale of Assets | -0.08 | 0.01 | 0.12 | 0.04 | 0.1 | -0.29 |
Asset Writedown | -0.16 | -0.16 | -0.27 | -0.12 | -0.37 | -0.02 |
Other Unusual Items | 0.52 | -1.16 | 4.7 | 0.43 | 10.91 | -1.75 |
Pretax Income | 94.69 | 22.05 | 292.99 | 196.32 | 147.1 | 53.28 |
Income Tax Expense | 14.99 | 1.56 | 39.82 | 18.12 | 20.18 | 9.46 |
Net Income | 79.7 | 20.5 | 253.18 | 178.2 | 126.92 | 43.82 |
Net Income to Common | 79.7 | 20.5 | 253.18 | 178.2 | 126.92 | 43.82 |
Net Income Growth | 12.73% | -91.91% | 42.07% | 40.41% | 189.66% | -74.48% |
Shares Outstanding (Basic) | 438 | 512 | 460 | 438 | 401 | 391 |
Shares Outstanding (Diluted) | 438 | 512 | 460 | 438 | 401 | 391 |
Shares Change (YoY) | -23.78% | 11.31% | 5.16% | 9.09% | 2.75% | -2.52% |
EPS (Basic) | 0.18 | 0.04 | 0.55 | 0.41 | 0.32 | 0.11 |
EPS (Diluted) | 0.18 | 0.04 | 0.55 | 0.41 | 0.32 | 0.11 |
EPS Growth | 47.89% | -92.73% | 35.10% | 28.71% | 181.91% | -73.82% |
Free Cash Flow | 114.15 | -136.11 | 112.51 | 281.39 | 147.24 | 79.57 |
Free Cash Flow Per Share | 0.26 | -0.27 | 0.24 | 0.64 | 0.37 | 0.20 |
Dividend Per Share | 0.050 | 0.050 | 0.357 | 0.332 | 0.332 | 0.332 |
Dividend Growth | -86.00% | -86.00% | 7.69% | - | - | -13.35% |
Gross Margin | 56.09% | 43.81% | 56.15% | 49.04% | 53.03% | 47.69% |
Operating Margin | 11.35% | 4.42% | 28.68% | 24.59% | 23.39% | 16.46% |
Profit Margin | 8.63% | 2.98% | 23.72% | 20.10% | 16.74% | 6.93% |
Free Cash Flow Margin | 12.35% | -19.79% | 10.54% | 31.74% | 19.42% | 12.58% |
EBITDA | 172.47 | 94.79 | 366.14 | 270.52 | 228.63 | 155.16 |
EBITDA Margin | 18.67% | 13.78% | 34.31% | 30.51% | 30.16% | 24.52% |
D&A For EBITDA | 67.55 | 64.36 | 60.1 | 52.52 | 51.31 | 51.03 |
EBIT | 104.92 | 30.43 | 306.04 | 217.99 | 177.33 | 104.13 |
EBIT Margin | 11.35% | 4.42% | 28.68% | 24.59% | 23.39% | 16.46% |
Effective Tax Rate | 15.83% | 7.06% | 13.59% | 9.23% | 13.72% | 17.76% |
Revenue as Reported | 924.04 | 687.79 | 1,067 | 886.57 | 758.16 | 632.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.